Sorensen Steffen Filskov, Carus Andreas, Meldgaard Peter
Department of Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark.
Department of Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark.
Lung Cancer. 2015 May;88(2):167-73. doi: 10.1016/j.lungcan.2015.02.010. Epub 2015 Feb 21.
Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. Vinorelbine can also be administered orally. However, the efficacy of orally administrated vinorelbine in adjuvant treatment of NSCLC is unknown. We assessed the overall survival (OS) and disease-free survival (DFS) of patients treated with adjuvant i.v. vinorelbine or p.o. vinorelbine, in combination with i.v. cisplatin.
We reviewed two time-separated cohorts of patients referred to the Department of Oncology at Aarhus University Hospital (Denmark) from 2005 to 2012 for adjuvant chemotherapy after surgery for NSCLC.
Of the 265 patients included in this study, 126 patients received i.v. and 139 received p.o. vinorelbine/cisplatin. The two groups were comparable with respect to important baseline characteristics. Median OS for all patients was 78.7 months and the median DFS was 35.7 months. No statistically significant difference in OS or DFS for patients treated with i.v. or oral vinorelbine was detected. The DFS rates of the two groups were comparable across all variables in subgroup analysis. In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival.
静脉给予顺铂和长春瑞滨是早期非小细胞肺癌（NSCLC）术后既定的辅助化疗方案。长春瑞滨也可以口服给药。然而，口服长春瑞滨在NSCLC辅助治疗中的疗效尚不清楚。我们评估了接受静脉注射长春瑞滨或口服长春瑞滨联合静脉注射顺铂治疗的患者的总生存期（OS）和无病生存期（DFS）。
我们回顾了2005年至2012年转诊至丹麦奥胡斯大学医院肿瘤科接受NSCLC术后辅助化疗的两个不同时间段的患者队列。
本研究纳入的265例患者中，126例接受静脉注射长春瑞滨，139例接受口服长春瑞滨/顺铂。两组在重要的基线特征方面具有可比性。所有患者的中位OS为78.7个月，中位DFS为35.7个月。未检测到静脉注射或口服长春瑞滨治疗的患者在OS或DFS方面有统计学显著差异。在亚组分析中，两组的DFS率在所有变量上均具有可比性。总之，我们观察到NSCLC术后静脉或口服长春瑞滨联合顺铂治疗在总生存期和无病生存期方面似乎同样有效。
